Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676457 | 0.86 | NPC1 (0.45) | PTGS2PTGS1MEN1NPC1RAB9A | |
| SCHEMBL3219976 | 0.85 | KMT2A (0.44) | PTGS2PTGS1MEN1NPC1RAB9A | |
| SCHEMBL3223168 | 0.75 | MAPT (0.56) | PTGS2PTGS1MEN1NPC1RAB9A | |
| SCHEMBL3223391 | 0.75 | MAPT (0.76) | PTGS2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3226759 | 0.75 | NPC1 (0.55) | PTGS1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL28748681 | 0.75 | MEN1 (0.59) | PTGS2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL28748631 | 0.74 | MEN1 (0.59) | PTGS2PTGS1MEN1NPC1RAB9A | |
| SCHEMBL22946643 | 0.74 | MAPT (0.55) | MEN1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL1712561 | 0.74 | ADORA3 (0.54) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL28544979 | 0.74 | ESR2 (0.51) | MEN1NPC1RAB9AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | claimed |
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2012-06-14 | — | — | US | disclosed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| EP-2176230-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-21 | — | — | EP | disclosed |
| EP-2170325-A2 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2010-04-07 | — | — | EP | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| WO-2009021747-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009019505-A2 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986643-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091107-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | PTGS2 4079/4885PTGS1 2601/4885MEN1 2802/4885 |
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, ACVR2B, CPT1B | PTGS2 3442/4885PTGS1 3139/4885MEN1 2807/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | PTGS2 2866/4885PTGS1 2434/4885MEN1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.